USOO6555547B1 (12) United States Patent (10) Patent No.: US 6,555,547 B1 Pamukcu et al. (45) Date of Patent: Apr. 29, 2003 (54) METHOD FOR TREATING A PATIENT WITH 5,239,083 A 8/1993 Kumazawa et al. NEOPLASA BY TREATMENT WITH A 5,250,535 A 10/1993 Verheyden et al. VINCA ALKALOID DERVATIVE 5,254,571 A 10/1993 Coates et al. 5,358,952 A 10/1994 Moschel et al. (75) Inventors: Rifat Pamukcu, Spring House, PA 5,376,683 A 12/1994 Klar et al. (US); Joseph M. Lobacki, North 5,393,755 A 2/1995 Neustadt et al. s s 5,401.774 A 3/1995 Pamuckcu et al. Wales, PA (US) 5.439,895 A 8/1995 Lee et al. (73) Assignee: Cell Pathways, Inc., Horsham, PA (US) 3. A 19. t cal 5,614,530 A 3/1997 Kumar et al. (*) Notice: Subject to any disclaimer, the term of this 5,614,627 A 3/1997 Takase et al. patent is extended or adjusted under 35 5,674,876. A 10/1997 Gilbert et al. U.S.C. 154(b) by 0 days. 5,696,159 A 12/1997 Gross et al. 5,728,563 A 3/1998 Toshio et al. 5,731,167 A 3/1998 Stracke et al. (21) Appl. No.: 09/515,714 5,756.818 A 5/1998 Buchmann et al. (22) Filed: Feb. 28, 2000 5,798.246 A 8/1998 Au-Young et al. 5,798.373 A 8/1998 Warrellow 5,849,770 A 12/1998 Head et al. (51) Int. C.7 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A61K 31/44 5,852,035 A 12/1998 Pamukcu et al. (52) U.S. Cl. ....................... 514/283; 514/322; 514/321; 5,858,694. A 1/1999 Piazza et al. 514/468; 514/568 5,869,519 A 2/1999 Karanewsky et al. (58) Field of Search ................................. 514/321, 283, 5,874.440 A 2/1999 Pamukcu et al. 514/322, 468, 568 5,891,896 A 4/1999 Warrellow et al. 5,922,595 A 7/1999 Fisher et al. 5,932,423 A 8/1999 Au-Young et al. (56) References Cited 5,932,465. A 8/1999 Loughney U.S. PATENT DOCUMENTS 5,942,520 A 8/1999 Pamukcu et al. 5.948,779 A 9/1999 Sperl et al. 3,031,450 A 4/1962 Fischer et al. 3,161,654. A 12/1964 Shen FOREIGN PATENT DOCUMENTS 3,322,755 A 5/1967 Rochet al. 3,517,005 A 6/1970 Cronin et al. DE 3O38166 5/1981 3,594,480 A 7/1971 Cronin et al. DE 274218 12/1989 3,647.858 A 3/1972 Hinkley et al. EP O 330 004 A1 6/1989 3,654,349 A 4f1972 Shen et al. EP O 347146 A2 12/1989 3,780,040 A 12/1973 Schnettler et al. EP O 349239 A2 1/1990 3.812,127 A 5/1974 Cronin et al. EP O 351058 1/1990 3,819,631 A 6/1974 Broughton et al. EP O352960 A2 1/1990 3,865,840 A 2/1975 Carson (List continued on next page.) 3,920,636 A 11/1975 Takahasi et al. 4,001.237 A 1/1977 Partyka et al. OTHER PUBLICATIONS 4,001.238 A 1/1977 Partyka et al. 4,039,544 A 8/1977 Broughton et al. Charalambous et al., “Inhibition of colon cancer precursors 4,060.615 A 11/1977 Matier et al. in the rat by Sulindac Sulphone is not dependent on inhibition S; A 3E's y al. of prostaglandin Synthesis.”, Abstract to Journal of Gastro 4,098,788 A 7/1978 E.We al. enterology and Hepatology, vol. 11, No. 4, pp. 307-310, 4,101,548. A 7/1978 Crenshaw et al. 1996.* 4,102.885. A 7/1978 Crenshaw et al. Alberts et al., “Do NSAIDS exert their colon cancer chemo 4,138,561 A 2/1979 Crenshaw et al. prevention activities through the inhibition of mucosal pros 4,146,718 A 3/1979 Jenks et al. taglandin synthetase?”, Abstract to J. Cell. Biochem. (Suppl. 4,161,595 A 7/1979 Kaplan et al. 22), pp. 18–23, 1995.* 4,171,363 A 10/1979 Crenshaw et al. Windholz et al., Editor-in-Chief of the Merck Index, An E. A 3E Shaw et al. Encyclopedia of Chemicals, Drugs and Biologicals, 10Th 4423.075 A 12/1983 Dvornik et al. Edition, Jul. 21, 1986, Nos. 9784-9788 and 9789.* 4,460,5904,457,927 A 7/1984 M6Biere Iler et al. (ListLi continuedinued on next page.) 4,837.2394,460,591 A 6/19897/1984 BenjaminDeGraw et et al. al. Primary Examiner-Dwayne C. Jones 4,880,810 A 11/1989 Lowe, III et al. (74) Attorney, Agent, or Firm-Robert W. Stevenson 4.885,301 A 12/1989 Coates (57) ABSTRACT 4923,874 A 5/1990 McMahon et al. 4,971,972 A 11/1990 Doll et al. This invention provides a method for treating a patient with 5,073,559 A 12/1991 Coates neoplasia by an adjuvant therapy that includes treatment ... A 3 E3 Althit al. with an antineoplastic Vinca alkaloid derivative. 5,175,151 A 12/1992 Afonso et al. 5,223,501 A 6/1993 Chakravarty et al. 17 Claims, 29 Drawing Sheets US 6,555,547 B1 Page 2 FOREIGN PATENT DOCUMENTS Antonenko S.G. et al., The role of the components of the cyclic nucleotide System in N-nitroSodiethylamine-induced EP O 395328 A2 10/1990 EP O 428268 A2 5/1991 hepatic carcinogenesis in rats (Article in Russian), Eksp. EP O 463756 A1 1/1992 Onkol. 1990; 12(5):18-21. EP O 48.5157 A2 5/1992 Badrieh, Y., et al., Chem. Ber, vol. 125, pp. 667-674 (1992). EP O 485.158 A2 5/1992 Barnett, Mary S. et al., Initial biochemical and functional EP O 485.171 A2 5/1992 characterization of cyclic nucleotide phosphodiesterase EP O 485172 A2 5/1992 isozymes in canine colonic Smooth muscle (Abstract Only), EP O 485.173 A2 5/1992 EP O 508586 A1 10/1992 J. Pharmacol. Exp. Ther..., 264(2) pp. 801-812 (1993). EP O 526004 A1 2/1993 Basu, S. and Kolesnick, R. StreSS Signals for apoptosis: EP O 607439 A1 7/1994 ceramide and c-Jun kinase. Oncogene, 17: 3277-85, 1998. EP O 7433O4 A1 5/1996 Belousova, A. K. et al., Role of cyclic nucleotides in tumor EP O 722937 A1 7/1996 growth regulation, (Article written in Russian) Vestn. Akad. GB 807826 1/1959 Med, Nauk SSSR (1980), (6), 86–9. GB 2063249 A 6/1981 Beltman, Jerlyn et al., Characterization of cyclic nucleotide JP 56-53659 A 5/1981 phosphodiesterases with cyclic GMP analogs: topology of JP 57-167974. A 10/1982 the catalytic domains, Mol. Pharmacol. (1995), 47(2), JP 8-311035 11/1996 330-9. WO WO 92/03419 3/1992 WO WO 93/07 149 4/1993 Bergstrand, Hakan et al., Effects of Antiallergic Agents, WO WO 93/12095 6/1993 Compound 48/80, and Some Reference Inhibitors on the WO WO 94/05661 3/1994 Activity of Partially Purified Human Lung Tissue Adenosine WO WO 94/19351 9/1994 Cyclic 3',5'-Monophosphate and Guanosine Cyclic WO WO 94/29277 12/1994 3',5'-Monophosphate Phosphodiesterase, Molecular Phar WO WO 95 18969 A 7/1995 macology, 13, pp. 38–43 (1976). WO WO95/26743 10/1995 WO WO 97/03070 1/1997 Biddle, William et al., Antineoplastic Effect of the Pyrimi WO WO 97/03985 2/1997 do-Pyrimidine Derivative: RA 233, Pathologie Biologie, WO WO 97/24334 7/1997 Jan., 1984, pp. 9-13. WO WO 98/14448 4/1998 Bjamason et al., Gastroenterology, Vol. 94, No. 4, pp. WO WO 98/15530 4/1998 1070–1074 (1988). WO WO 98/16224 4/1998 Blaya, C. et al., Effect of the protein kinase inhibitors, WO WO 98/16521 4/1998 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 and WO WO 98/17668 4/1998 WO WO 98/08848 5/1998 N-(2-methylaminoethyl)-5-isoquinoline-sulfonamide WO WO 98/23597 6/1998 H-8 on Lewis lung carcinoma tumor progression, European WO WO 98/381.68 9/1998 Journal of Pharmacology, 354, pp. 99-104 (1998). WO WO 96/32379 10/1998 Brogden, R.N. et al., Drugs, vol. 16, pp. 97-114 (1978). Broughton, B.J. et al., Antiallergic Activity of OTHER PUBLICATIONS 2-Phenyl-8-azapruin-6-ones, Journal of Medicinal Chem Earnest, D. et al., PiroXicam and Other Cyclooxygenase istry, vol. 18, No. 11, pp. 1117–1118 (1975). Inhibitors: Potential for Cancer Chemoprevention, Journal Butt, E., Eigenthaler, M., and Genieser, H. G. of Cellular Biochemistry, Supplement 161:156–166, 1992.* (Rp)-8-pCPT-cGMPs, a novel c(GMP-dependent protein Neit “Oncologic, Endocrine & Metabolic-Treatments, kinase inhibitor. Eur J Pharmacol, 269: 265–8, 1994. topics and trends in ovarian cancer, Exp. Opin. Invest. Butt, Elke et al., Characterization of cyclic nucleotide phos Drugs 4(12): 1205-1216, (1995).* phodiesterases with cyclic AMP analogs: topology of the Ahlstrom, M., Lamberg-Allardt, C., Regulation of adenos catalytic sites and comparison with other cyclic AMP-bind ine 3',5'-cyclic monophosphate (cAMP) accumulation in ing proteins, Mol. Pharmacol. (1995), 47(2), 340-7. UMR-106 osteoblastlike cells: role of cAMP-phosphodi Cardone, M. H., Salvesen, G. S., Widmann, C., Johnson, G., esterase and cAMP efflux, Biochem. Pharmacol. (1999), and Frisch, S. M. The regulation of anoikis: MEKK-1 58(8), 1335–1340.